# Nuclide record idea-alpha-for-oligometastatic-disease (idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/ideas/idea-alpha-for-oligometastatic-disease/>
  a schema:CreativeWork ;
  nuclide:kind "idea" ;
  schema:identifier "idea-alpha-for-oligometastatic-disease" ;
  schema:name "Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer"@en ;
  schema:description "When prostate cancer comes back in just a handful of spots, doctors already zap those spots with precision radiotherapy. Adding a single dose of an alpha-particle radioactive drug at the same time, instead of the more established beta-particle version, might mop up cancer cells too small to see on a scan, because alpha radiation travels a much shorter distance and hits harder in that short range."@en ;
  schema:url <https://nuclide.cc/ideas/idea-alpha-for-oligometastatic-disease/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07150715>, <https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-05583>, <https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.TPS282>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7490874/> ;
  nuclide:tag "alpha therapy", "oligometastatic", "prostate" ;
  nuclide:related <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/terms/oligometastatic/>, <https://nuclide.cc/ideas/idea-psma-pet-guided-mdt/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> .